Sourav Bandyopadhyay, PhD
Professor
Bioengineering
School of Pharmacy
Sourav Bandyopadhyay obtained his PhD in Bioinformatics and Systems Biology with Trey Ideker (UC San Diego) where he made seminal contributions to our understanding of the organization and plasticity of physical and genetic interaction networks, (Bandyopadhyay et al. Science 2010, Nature Methods 2010, PLoS Computational Biology 2008).
Show full bio (160 words) Hide full bio
In 2010 he began an independent research career through the prestigious UCSF faculty fellowship designed to provide early independence to the world’s best scientists.
The Bandyopadhyay lab employs new cellular and molecular technologies to tackle the most urgent and clinically important problems in cancer therapy, including functional genomics, drug screens, proteomics and single cell approaches. Critically, these technologies often generate the scale and complexity of data that necessitate the development of new computational algorithms to maximize their impact and fully understand their relevance in the clinic. The lab is focused on identifying mechanisms of drug resistance and targetable synthetic lethal interactions in breast and lung cancers since these diseases are deadly in the metastatic setting and demonstrate suboptimal tumor responses even with out best, most targeted therapies. We are committed to the identification, mechanistic dissection and clinical translation of new targets and target combinations through broad collaborations with biotechnologists, chemists, clinicians and pharma.
Interests
Show all (7) Hide
- networks
- cancer biology
- precision medicine
- pathways
- bioinformatics
- pharmacogenomics
- systems biology
Websites
Show all (3) Hide
- @@SBLabUCSF on Twitter (twitter.com)
- Lab Website (cancersignaling.net)
- Profile at UCSF Cancer Center (cancer.ucsf.edu)
Grants and Projects
Show all (4) Hide
- Stress responses drive resistance and shape tumor evolution in EGFR mutant lung cancer, NIH, 2020-2025
- The Cancer Target Discovery and Development Network at UCSF, NIH, 2017-2022
- Physical and Genetic Interaction Landscape of the Tyrosine Kinome, NIH, 2014-2019
- Multiscale analysis of influenza host-pathogen interactions: Fluomics, NIH, 2013-2018
Publications (72)
Top publication keywords:
PharmacogeneticsProtein Interaction MappingProtein Kinase InhibitorsGene Regulatory NetworksAurora Kinase ADrug Resistance, NeoplasmBreast NeoplasmsCell Line, TumorAzepinesPlant ProteinsAntineoplastic AgentsEpistasis, GeneticSynthetic Lethal MutationsPoly(ADP-ribose) Polymerase InhibitorsTriple Negative Breast Neoplasms
-
Abstract 4653: Unraveling the vulnerabilities of targeted therapy-tolerant persister cells in NSCLC.
Cancer Research 2024 Donghwa Kim, Dmitry Kuchenov, Aubhishek Zaman, Neal Bennett, Emilio Ramos, Ken Nakamura, Arun P. Wiita, Sourav Bandyopadhyay, Trever Bivona -
An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer.
Scientific reports 2024 Jacobo Jacobo M, Donnella HJ, Sobti S, Kaushik S, Goga A, Bandyopadhyay S -
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Frontiers in oncology 2023 Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M -
A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer.
Oncogene 2023 Meng D, Zhao X, Yang YC, Navickas A, Helland C, Goodarzi H, Singh M, Bandyopadhyay S -
Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Cancer research 2022 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR
Show all (67 more) Hide
-
Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Cancer research 2022 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR -
Novel Regulators of Macropinocytosis-Dependent Growth Revealed by Informer Set Library Screening in Pancreatic Cancer Cells.
Metabolites 2022 Kim SH, Song JH, Kim MJ, Song MG, Ku AA, Bandyopadhyay S, McCormick F, Kim SE -
Abstract PO017: HBV alters YAP regulation in liver cancer by remodeling PP2A complexes.
Clinical Cancer Research 2022 John Gordan, Adriana Pitea, Rigney E Turnham, Manon Eckhardt, Gwendolyn M Jang, Huat Lim, Alex L Choi, Sourav Bandyopadhyay, Danielle Swaney, Kevan Shokat, Trey Ideker, Nevan Krogan -
Trans-channel fluorescence learning improves high-content screening for Alzheimer's disease therapeutics.
Nature machine intelligence 2022 Wong DR, Conrad J, Johnson N, Ayers J, Laeremans A, Lee JC, Lee J, Prusiner SB, Bandyopadhyay S, Butte AJ, Paras NA, Keiser MJ -
UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.
Proceedings of the National Academy of Sciences of the United States of America 2021 Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Kim SE -
Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR -
Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
Journal of Clinical Oncology 2021 Collin M. Blakely, Matthew A. Gubens, Gregory M. Allen, Shrusti Shah, Matthew Jereza, Bianca Bacaltos, Sourav Bandyopadhyay -
Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer.
EBioMedicine 2021 Kim D, Bandyopadhyay S -
Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.
Molecular cancer therapeutics 2020 Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL -
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Cell 2020 Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA… -
Abstract 1470: UGP2 is a critical regulator of protein glycosylation in pancreatic cancer.
Cancer Research 2020 Andrew L. Wolfe, Jacqueline Galeas, Eneda Toska, Qing Zhou, Angel Ku, Richard P. Koche, Sourav Bandyopadhyay, Carlito B. Lebrilla, Maurizio Scaltriti, Frank McCormick, Sung Eun Kim -
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
The Journal of investigative dermatology 2020 Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ -
Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
Nature communications 2020 Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S -
B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC.
Journal of Thoracic Oncology 2020 F. Haderk, C. Fernández-Méndez, K.N. Shah, W. Wu, J. Guan, J. Rotow, D. Allegakoen, V. Olivas, S. Bandyopadhyay, C. Kuo, T. Bivona -
Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models.
Blood 2019 CHI-HENG WU, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark … -
Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC.
Tumor Biology 2019 Khyati N. Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Victoria E. Wang, Jonathan Kuhn, Sophie Dumont, Frank Mccormick, Andrei Goga, Collin M. Blakely, Trever G. Bivona, Sourav … -
Targeting the evolution of drug resistance in lung cancer.
Molecular & cellular oncology 2019 Shah KN, Bandyopadhyay S -
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Nature medicine 2018 Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, … -
Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics.
Cell systems 2018 Webber JT, Kaushik S, Bandyopadhyay S -
P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer.
Journal of Thoracic Oncology 2018 K. Shah, C. Blakely, T. Bivona, S. Bandyopadhyay -
Abstract A45: Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer.
Resistance Mechanisms 2018 Hayley Donnella, James Webber, Kevan Shokat, Andrei Goga, John Gordan, Sourav Bandyopadhyay -
Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Experimental and Molecular Therapeutics 2018 Khyati N. Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Golzar Golzar Hemmati, Gregor Krings, Henry J. Haringsma, Andrew D. Simmons, Thomas C. Harding, Andrei Goga, Collin Blakely, … -
Abstract 3297: A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer.
Bioinformatics and Systems Biology 2018 Swati Kaushik, Gwendolyn Jang, Hsien-Ming Hu, Khyati Shah, Xin Zhao, John Jascur, John Von Dollen, Erik Verschueren, Jeffrey Johnson, Nevan Krogan, Sourav Bandyopadhyay -
Abstract 798: Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma.
Experimental and Molecular Therapeutics 2018 Chi-Heng Wu, Chen-Yen Yang, Taha Rakhshandhroo, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick, Weiyun Ai -
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.
Nature chemical biology 2018 Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S -
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.
Cell reports 2018 Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S -
Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Cancer research 2018 Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR -
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.
eLife 2018 Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA -
Abstract PR04: HER3 crosstalk with HPV16-E6E7 is a feedback resistance mechanism to PI3K-targeted therapies in head and neck cancer.
Viral Cancers HPV/EBV 2017 Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Hua Li, Yan Zeng, Rachel O'Keefe, Max V. Ranall, Sourav Bandyopadhyay, Margaret Soucheray, Danielle L. Swaney, Nevan Krogan, Carolyn Kemp, Umamaheswar … -
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR -
Connecting tumor genomics with therapeutics through multi-dimensional network modules
BioArxiv 2016 Webber JT, Ranall MV, Kaushik S, Bandyopadhyay S. -
Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity.
ACS chemical biology 2016 Kohnz RA, Roberts LS, DeTomaso D, Bideyan L, Yan P, Bandyopadhyay S, Goga A, Yosef N, Nomura DK -
Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer.
Experimental and Molecular Therapeutics 2016 Toni Michel Brand, Stefan Hartmann, Neil Bhola, Noah D. Peyser, Hua Li, Yan Zeng, Max V. Randall, Sourav Bandyopadhyay, Jennifer R. Grandis -
Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndrome.
Experimental and Molecular Therapeutics 2016 Chen-Yen Yang, Razan Faraj, Taha Rakhshandaroo, Shervin Afghani, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick, Weiyun Ai -
Challenges in identifying cancer genes by analysis of exome sequencing data.
Nature communications 2016 Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel PS, Friend S, Ideker T -
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Molecular cancer therapeutics 2016 Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, … -
Abstract C88: Genomics, advocacy, and emerging therapeutics to address triple-negative breast cancer (TNBC) outcome disparities.
Community Groups and Advocacy 2016 Susan Samson, Alicia Y. Zhou, Maria Martins, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John Gordan, Rebecca Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino,… -
Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary Syndrome.
Blood 2015 Weiyun Ai, Chen-Yen Yang, Razan Faraj, Taha Rakhshandhroo, Shervin Afghani, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick -
Abstract B44: A systems approach combining genomics, advocacy, and emerging novel therapeutics to address triple-negative breast cancer (TNBC) outcomes disparities.
Organ Site Research 2015 Alicia Y. Zhou, Maria M. Martins, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John D. Gordan, Rebecca S. Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, … -
Abstract B48: Identification of novel drug interactions with MYC via a quantitative chemical-genetic interaction map.
Therapeutic Translation 2015 Alicia Y. Zhou, Maria M. Martins, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John D. Gordan, Rebecca S. Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, … -
Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions.
Cancer research 2015 Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F -
Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer.
ACS chemical biology 2015 Kohnz RA, Mulvihill MM, Chang JW, Hsu KL, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, Nomura DK -
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
Cell reports 2015 Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, … -
Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.
Cancer discovery 2014 Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat … -
73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer.
European Journal of Cancer 2014 M. Sos, R.S. Levin, J.D. Gordan, J.A. Oses-Prieto, J.T. Webber, M. Salt, B. Hann, A.L. Burlingame, F. McCormick, S. Bandyopadhyay, K.M. Shokat -
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
Cell reports 2014 Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM -
Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness.
ACS chemical biology 2014 Benjamin DI, Louie SM, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng SW, Nomura DK -
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
Proceedings of the National Academy of Sciences of the United States of America 2014 Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG -
Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation.
Cancer discovery 2013 Salt MB, Bandyopadhyay S, McCormick F -
Operational Signaling Pathways in Radiation-Induced Tumors.
International Journal of Radiation Oncology • Biology • Physics 2013 S.E. Braunstein, R. Mroue, B. Huang, S. Bandyopadhyay, J. Nakamura -
Bringing it all together: big data and HIV research.
AIDS (London, England) 2013 Bushman FD, Barton S, Bailey A, Greig C, Malani N, Bandyopadhyay S, Young J, Chanda S, Krogan N -
Quantitative genetic-interaction mapping in mammalian cells.
Nature methods 2013 Roguev A, Talbot D, Negri GL, Shales M, Cagney G, Bandyopadhyay S, Panning B, Krogan NJ -
Rewiring of genetic networks in response to DNA damage.
Science (New York, N.Y.) 2010 Bandyopadhyay S, Mehta M, Kuo D, Sung MK, Chuang R, Jaehnig EJ, Bodenmiller B, Licon K, Copeland W, Shales M, Fiedler D, Dutkowski J, Guénolé A, van Attikum H, Shokat KM, Kolodner RD, Huh WK, … -
Coevolution within a transcriptional network by compensatory trans and cis mutations.
Genome research 2010 Kuo D, Licon K, Bandyopadhyay S, Chuang R, Luo C, Catalana J, Ravasi T, Tan K, Ideker T -
A human MAP kinase interactome.
Nature methods 2010 Bandyopadhyay S, Chiang CY, Srivastava J, Gersten M, White S, Bell R, Kurschner C, Martin C, Smoot M, Sahasrabudhe S, Barber DL, Chanda SK, Ideker T -
Human host factors required for influenza virus replication.
Nature 2010 König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy… -
Evolutionarily conserved herpesviral protein interaction networks.
PLoS pathogens 2009 Fossum E, Friedel CC, Rajagopala SV, Titz B, Baiker A, Schmidt T, Kraus T, Stellberger T, Rutenberg C, Suthram S, Bandyopadhyay S, Rose D, von Brunn A, Uhlmann M, Zeretzke C, Dong YA, Boulet H, Koegl … -
Host cell factors in HIV replication: meta-analysis of genome-wide studies.
PLoS pathogens 2009 Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H, Hazuda DJ, Espeseth AS, König R, Bandyopadhyay S, Ideker T, Goff SP, Krogan NJ, Frankel AD, Young JA, Chanda SK -
A genetic interaction map of RNA-processing factors reveals links between Sem1/Dss1-containing complexes and mRNA export and splicing.
Molecular cell 2008 Wilmes GM, Bergkessel M, Bandyopadhyay S, Shales M, Braberg H, Cagney G, Collins SR, Whitworth GB, Kress TL, Weissman JS, Ideker T, Guthrie C, Krogan NJ -
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.
Cell 2008 König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, … -
Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast.
Science (New York, N.Y.) 2008 Roguev A, Bandyopadhyay S, Zofall M, Zhang K, Fischer T, Collins SR, Qu H, Shales M, Park HO, Hayles J, Hoe KL, Kim DU, Ideker T, Grewal SI, Weissman JS, Krogan NJ -
Functional maps of protein complexes from quantitative genetic interaction data.
PLoS computational biology 2008 Bandyopadhyay S, Kelley R, Krogan NJ, Ideker T -
Integrating physical and genetic maps: from genomes to interaction networks.
Nature reviews. Genetics 2007 Beyer A, Bandyopadhyay S, Ideker T -
Systematic identification of functional orthologs based on protein network comparison.
Genome research 2006 Bandyopadhyay S, Sharan R, Ideker T -
Discovering regulated networks during HIV-1 latency and reactivation.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2006 Bandyopadhyay S, Kelley R, Ideker T -
The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization.
Proceedings of the National Academy of Sciences of the United States of America 2004 Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR -
Evolutionary and functional relationships within the DJ1 superfamily.
BMC evolutionary biology 2004 Bandyopadhyay S, Cookson MR